Emerging European Biotechnology Organization Awards Studies to eResearchTechnology Totaling $1.3 Million for Cardiac Safety Moni
March 29 2004 - 8:06AM
PR Newswire (US)
Emerging European Biotechnology Organization Awards Studies to
eResearchTechnology Totaling $1.3 Million for Cardiac Safety
Monitoring and Information Distribution Services Awards Include a
Series of Late Phase Studies for Two Key Clinical Development
Programs PHILADELPHIA, March 29 /PRNewswire-FirstCall/ --
eResearchTechnology, Inc. (eRT), , a leading provider of
centralized electrocardiographic (ECG) collection and
interpretation services, announced today that it has been awarded
studies totaling more than $1.3 million in cardiac safety
monitoring and services from an emerging European biotechnology
organization for two of its key drug candidates in later phase
clinical trials. The awards cover a series of Phase III studies
that target the two compounds and will be conducted at 163 research
sites distributed across five continents. eRT will provide
comprehensive support and 163 units of digital 12-lead ECG
equipment designed to facilitate collection of cardiac safety data
that is subsequently provided to eRT for analysis. eRT will perform
digital collection, measurement, interpretation, review, and
distribution of cardiac safety data through its EXPeRT workflow
enabled data handling technology, the first solution in production
that was designed explicitly to meet emerging international
regulatory guidance and technical standards. "We are delighted with
these agreements, which illustrate that the trend toward program
level awards for significant later phase studies is continuing to
gain momentum across all segments and geographies of the drug
development industry," said Scott Grisanti, senior vice president
of business development and chief marketing officer at eRT. "We
look forward to working closely with this sponsor to ensure
effective conduct of cardiac safety services for these two
compounds in the critical stages of the path to commercialization."
Based in Philadelphia, PA, eResearchTechnology, Inc.
(http://www.ert.com/) is a provider of technology and services to
the pharmaceutical, biotechnology and medical device industries on
a global basis. The company is a market leader in providing
centralized core-diagnostic electrocardiographic (ECG) technology
and services to evaluate cardiac safety in clinical development.
The company is also a leader in providing technology and services
to streamline the clinical trials process by enabling its customers
to automate the collection, analysis, and distribution of clinical
data in all phases of clinical development. Statements included in
this release may constitute forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995.
Such statements involve a number of risks and uncertainties such as
competitive factors, technological development, market demand, and
the company's ability to obtain new contracts and accurately
estimate net revenues due to variability in size, scope and
duration of projects, and internal issues in the sponsoring client.
The studies pertaining to these awards may be canceled by the
sponsor at its sole discretion. As a result, actual results may
differ materially from any financial outlooks stated herein.
Further information on potential factors that could affect the
company's financial results can be found in the company's Reports
on Forms 10-K and 10-Q filed with the Securities and Exchange
Commission. DATASOURCE: eResearchTechnology, Inc. CONTACT: Joan
Sterlacci, eResearchTechnology, Inc., +1-908-203-6473; or Matt
Hayden, Hayden Communications, +1-858-456-4533, for
eResearchTechnology Web site: http://www.ert.com/
Copyright
East Resources Acquisition (NASDAQ:ERES)
Historical Stock Chart
From Jun 2024 to Jul 2024
East Resources Acquisition (NASDAQ:ERES)
Historical Stock Chart
From Jul 2023 to Jul 2024
Real-Time news about East Resources Acquisition Company (NASDAQ): 0 recent articles
More Eresearch Tech (MM) News Articles